SIG
AST

Stanford Investment Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Stanford Investment Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-20
Closed – – 361
2016
Q4 		$0 Hold
20
– – ﹤0.01% 429
2016
Q3 		$0 Hold
20
– – ﹤0.01% 422
2016
Q2 		$0 Hold
20
– – ﹤0.01% 372
2016
Q1 		$0 Hold
20
– – ﹤0.01% 375
2015
Q4 		$0 Hold
20
– – ﹤0.01% 363
2015
Q3 		$0 Hold
20
– – ﹤0.01% 372
2015
Q2 		$0 Hold
20
– – ﹤0.01% 378
2015
Q1 		$0 Hold
20
– – ﹤0.01% 366
2014
Q4 		$0 Buy
+20
New +$81 ﹤0.01% 348

Other funds holding AST

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Stanford Investment Group's AST Position: Q1 2017 in Review

Stanford Investment Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2017, closing a stake of 20 shares.

Stanford Investment Group first reported a position in AST in Q4 2014 and held it in 9 quarters. The position peaked at $0 in Q4 2016. 66 funds tracked by Wall St. Rank hold AST as of Q1 2017.

  • Stanford Investment Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2017 after selling out during the quarter.
  • Stanford Investment Group sold 20 Asterias Biotherapeutics Inc. Series A shares in Q1 2017.
  • Stanford Investment Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 9 quarters.
  • Stanford Investment Group's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q4 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2017.

Based on Stanford Investment Group's 13F filing for Q1 2017.